InVivo Therapeutics Receives FDA Conditional Approval for Proposed Protocol Changes
InVivo Therapeutics (OTC: NVIV) announced today that it
has received conditional approval from the Food and Drug Administration
for proposed changes to the protocol and supporting documents for the
safety trial of its first investigational product, a degradable polymer
scaffold for spinal cord injury. InVivo submitted these proposed changes
to the FDA on November 21, 2013 and will follow the FDA's approval
conditions in their entirety in a submission to the FDA next week.